Par Pharma has posted a net income of $30.53m for the third quarter 2010, compared to $26.34m for the comparable period in 2009.
Operating income was $40.61m, compared to $42.38m for the comparable period in 2009.
Par Pharma has posted arevenue of $781.85m for the nine months ended 30 September 2010, compared to $902.84m for the year ago period.
For the nine months ended 30 September 2010, Par Pharma has posted a net income of $75.23m, compared to $66.23m for the year ago period.
Operating income was $108.1m, compared to $105.87m for the year ago period.
Par Pharma, through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, manufactures, develops and markets generic drugs and niche proprietary pharmaceuticals.